Bipartisan Bill Introduces Key Healthcare Reforms to Enhance Transparency and Access
On December 18, 2024, U.S. lawmakers unveiled a bipartisan stopgap funding bill to finance the federal government through March, incorporating significant healthcare provisions.
Eli Lilly CEO Discusses Speculations on Drug Pricing and Healthcare Priorities Under Trump
Following a dinner at Trump’s Mar-a-Lago estate last week, Eli Lilly CEO David Ricks pointed to raising drug prices in other developed nations as a key strategy to reduce costs in the United States.
ModEx: Revolutionizing Cancer Drug Pricing and Access Through Open-Source Health Economic Models
Discover how ModEx is transforming cancer drug pricing and accessibility by providing a decentralized platform for open-source health economic models. Learn about the innovative approach to model sharing, including royalty incentives for developers and enhanced validation for users, aimed at ensuring cost-effective healthcare solutions.
Battling the Superbug Crisis: Urgent Need for Innovative Solutions and Increased Funding
The escalating threat of antimicrobial resistance (AMR) is outpacing current efforts to develop effective treatments, leading [...]
RSV Vaccine Proves Effective in Preventing Severe Illness in Older Adults, Study Finds
A study published in The Lancet by the VISION Network shows the RSV vaccine is about 80% [...]
A Study on Reducing Drug Waste: How Smaller Leqembi Vials Could Save Medicare Millions
A recent study from a team at UCLA estimates that Medicare could lose between $133 million [...]
Breakthrough in CAR-T-Cell Therapy Using Donor-Derived Cells for Autoimmune Diseases
A new CAR-T-cell therapy using donor-derived, CRISPR-modified immune cells has successfully treated three people with severe [...]
Survival Analysis for Immature Data: A Review of Techniques and Lessons Learned
Watch to hear the techniques of survival analysis, their application in economic evaluations, and lessons learned from conducting survival analysis on immature data, addressing the challenges of analyzing different outcomes.
Beyond Accelerated Approvals: External Control Arms
Hear this panel's discussion on the strategic use of external control arms and, if done correctly, how they can help bring products to market in a shorter time and for lower costs.
Debating the Value and Cost of AI Mammogram Analysis in Breast Cancer Detection
Radiology clinics offer artificial intelligence (AI) analysis of mammograms for $40, but insurance doesn't cover it. [...]
Total System Value™ – A DYNAMIC APPROACH TO VALUE DEMONSTRATION
HEOR Ltd. have been working on an exciting new framework called Total System Value™. This episode of tHEORetically speaking features their CEO Phil McEwan and CGO Jeff Anderson to talk to us about this dynamic approach to value demonstration.
Total System Value™ – A DYNAMIC APPROACH TO VALUE DEMONSTRATION
HEOR Ltd. have been working on an exciting new framework called Total System Value™. This episode of tHEORetically speaking features their CEO Phil McEwan and CGO Jeff Anderson to talk to us about this dynamic approach to value demonstration.
FDA Approves Florida’s Plan to Import Prescription Drugs from Canada
The Biden administration has approved Florida Governor Ron DeSantis' plan to import certain prescription drugs from [...]
AstraZeneca Acquires Obesity Drug Developer Eccogene’s ECC5004 for $185 Million, Aiming at Type 2 Diabetes and Obesity Markets
AstraZeneca is acquiring obesity drug developer Eccogene's ECC5004 for $185 million with the potential to pay [...]
Biden Administration Shifts COVID-19 Treatment Distribution to Private Sector
The Biden administration is transitioning the distribution of millions of COVID-19 treatments from the government to [...]
New FDA-Approved Non-Hormonal Treatment for Menopause: Challenges and Future of Veozah Accessibility
Veozah, a new treatment for hot flashes in menopausal women, was approved by the FDA in [...]
Pfizer Announces Cost-Cutting Measures as Covid Vaccine and Antiviral Sales Decline
Pfizer has announced plans for a company-wide cost-cutting initiative this year and next due to expected [...]
Reformative Health Economists Propose Universal, Free Basic Care in New Book
"We’ve Got You Covered: Rebooting American Health Care" is a new book by health economists Liran Einav and Amy Finkelstein. [...]
Federal Judge Upholds Medicare Drug Price Negotiation Provisions of Inflation Reduction Act
A federal judge has upheld the Medicare drug price negotiation provisions of the Inflation Reduction Act (IRA), opposing the Chamber [...]
American Medical Association Issues Unique PLA Code to Oxford BioDynamics
Oxford BioDynamics PLC has been assigned a unique Proprietary Laboratory Analysis Code (PLA Code) by the American Medical Association's CPT [...]
Johnson & Johnson’s Drug Combination Improves Progression-Free Survival in Lung Cancer Trial Against AstraZeneca’s Therapy
The Mariposa study showed that a combination of two Johnson & Johnson (J&J) drugs, Rybrevant, and lazertinib, was successful in [...]
Integration of Digital Targeting in Addressable TV: Implications for Healthcare Marketers
Addressable TV—which uses digital targeting and measurements for television advertisements—is changing the marketing landscape. It allows healthcare marketers to reach [...]
Plans to Remove Medical Debt from Credit Reports and Further Measures Proposed to Alleviate Medical Debt Burden
The White House has announced a plan by the Consumer Financial Protection Bureau (CFPB) to exclude [...]
Alexion Pharmaceuticals Nears $125M Settlement in Class Action Lawsuit Over Alleged Unethical Sales Practices
A 2016 class action lawsuit against pharmaceutical company Alexion, which claimed that the company's unethical sales [...]
Pharmaceutical Companies Sue Biden Administration Over Alleged APA Violations in Medicare Drug Pricing Program
Pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim, are suing the Biden Administration over its plan to [...]
